Picture this: a pacemaker that doesn't need leads threading through your veins, or one that powers itself from your heartbeat. These aren't futuristic concepts — they're hitting the market now, and they're reshaping a medical device sector that's been remarkably stable for decades.
The global pacemaker market is experiencing its biggest transformation in years, with revenues expected to climb from $5.4 billion in 2024 to $7.5 billion by 2030. That 5.7% annual growth rate might seem modest, but it represents something profound happening in cardiac care.
The catalyst isn't just our aging population, though that's certainly a factor — with 1% to 2% of people over 70 eventually needing permanent pacemakers. What's really driving growth is the expansion of who gets these devices. Cardiac resynchronization therapy pacemakers are now being prescribed for patients with mild-to-moderate heart failure, not just severe cases. In Europe alone, more than 15 million people live with heart failure, and a growing subset qualifies for this therapy.
Meanwhile, leadless pacemakers are eliminating the need for surgical pockets and transvenous leads entirely. Companies like BIOTRONIK have introduced the world's first pacing system approved for left bundle branch area pacing, while startups are developing battery-free devices that harvest energy from cardiac motion itself.
Download the Free Report Overview:
